The IL-17 and IL-23 inhibitor classes, including those targeting the IL-17 receptor (brodalumab), IL-17 cytokine antagonists (secukinumab, ixekizumab, bimekizumab), and IL-23 cytokine antagonists (guselkumab, risankizumab, tildrakizumab)
Yes, body aches and muscle soreness occur in a subset of tirzepatide users, particularly in the first 12 weeks as metabolism rapidly shifts and fat breakdown accelerates
The split between Trustpilot (positive) and Reddit/BBB (very negative) is concerning
Artemisinin and l-carnitine combination research protocol alters the erythrocytes [PMID: 35293664] Laboratory literature summary: Artemisinin and l-carnitine combination research protocol alters the erythrocytes redox status
Additionally, a lot of these companies are putting, quote, unquote, additives and creating custom versions of these drugs
Here's the truth: these aren't the same medication with different names